Adaptive Biotechnologies (NASDAQ: ADPT) reported Q1 EPS of ($0.44), $0.01 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $38.6 million versus the consensus estimate of $37.71 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2022 revenue of $185-195 million, versus the consensus of $189.4 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.